Magic Lifescience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Magic Lifescience is an early-stage, private diagnostics company founded in 2020 and based in San Diego. It is developing the MagChipR™, a first-of-its-kind point-of-care molecular diagnostic analyzer designed to provide ultra-fast, multiplexed results for infectious diseases and antimicrobial susceptibility directly at the patient's side. The platform aims to address the critical need for rapid, definitive results to guide antibiotic therapy and improve patient outcomes. The company is currently in the pre-revenue, pre-commercial stage, with its technology still under development and not yet cleared for clinical use.

Infectious Diseases

Technology Platform

Giant Magnetoresistance (GMR) biosensor integrated with ultra-fast PCR on a lab-on-chip (LOC) cartridge for rapid, multiplexed molecular detection of pathogens and antimicrobial resistance (AMR) markers.

Opportunities

The global imperative to combat antimicrobial resistance (AMR) creates a massive market for rapid diagnostics that enable targeted antibiotic therapy.

Magic Lifescience's proposed sub-20-minute, combined pathogen/AMR test at the point of care could address a critical unmet need in hospital emergency departments, ICUs, and outpatient settings, potentially improving outcomes and reducing healthcare costs.

Risk Factors

The company faces extreme technical risk in developing a first-of-its-kind, integrated GMR/PCR lab-on-chip system.

Significant regulatory risk exists as the unapproved platform requires FDA clearance, a lengthy and costly process.

Commercialization risk is high, given the need to compete with established diagnostic companies and prove cost-effectiveness to healthcare providers.

Competitive Landscape

The rapid molecular diagnostics space is competitive, with established players like Cepheid (BioFire), Luminex, and Qiagen, and newer entrants like Visby Medical and Mammoth Biosciences. Magic Lifescience's differentiation hinges on its unique GMR detection technology and the ambitious goal of delivering pathogen+AMR results in under 20 minutes, a faster timeline than most current POC molecular systems.

More companies in Diagnostics & Precision Medicine →More companies in United States →